Consumergenetics has developed so fast that it became possible for consumers to obtain genome risk information based on single nucleotide polymorphisms data of over 250 diseases/conditions for just 99 USD. In November 2013, the American Food and Drug Administration (FDA) ordered the company 23andMe to stop returning health results because they found a lack of scientific evidence of the reposted disease risks. The ethical dilemmas associated with this are reviewed, and the recommendations are described in genome testing. Ethical dilemmas in relation direct-to-consumer testing are discussed.
|Tidsskrift||Ugeskrift for laeger|
|Status||Udgivet - 10 nov. 2014|
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine